CRNX Crinetics Pharmaceuticals Inc stock chart & analysis
Conviction 50HealthcareScan · Fri, Nov 6, 2026Crinetics Pharmaceuticals Inc (CRNX) closed at $84.95 on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 90, RS Rating 99, at a 52-week high, +82.5% year to date. Sector: Healthcare · Biotechnology.
CRNX technical analysis
Trend
CRNX is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 13.5% above the 50-day ($74.83) and 68.4% above the 200-day ($50.44). ADX(14) at 81 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 90, in overbought territory. The MACD histogram is negative. A bearish RSI divergence is in place. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.
Volume and volatility
It trades about $217.0M a day on average. ATR(14) is $0.4138, 0.5% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (-0.18) shows distribution.
Key levels
The chart pattern's support is $83.82 and its resistance $84.27. The 52-week range is $30.25 to $85.01, and price sits at the high. The VWAP anchored at the 52-week high is $84.96, above price.
Performance
CRNX returned +0.2% (1 week), +1.7% (1 month), +146.1% (3 months), +108.8% (6 months), +177.2% (1 year), +82.5% (year to date).
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Biotechnology · Listed 2018 · 594 employees
Congress activity
Disclosed STOCK Act trades in CRNX · 6 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Gilbert Cisneros house · D · CA · traded 2026-07-30 | Sell | $15K–$50K | 2026-07-30 | 2026-09-04 | |
Gilbert Cisneros house · CA · traded 2026-03-03 | Buy | $1K–$15K | 2026-03-03 | 2026-04-06 | |
Gilbert Cisneros house · D · CA · traded 2025-04-17 | Buy | $1K–$15K | 2025-04-17 | 2025-05-06 | |
 Josh Gottheimer house · D · NJ · traded 2025-03-19 | Sell | $1K–$15K | 2025-03-19 | 2025-04-10 | |
Gilbert Cisneros house · D · CA · traded 2025-01-29 | Buy | $1K–$15K | 2025-01-29 | 2025-02-11 | |
Josh Gottheimer house · NJ · traded 2024-09-25 | Buy | $1K–$15K | 2024-09-25 | 2024-10-03 |
Insider activity
SEC Form 4 transactions in CRNX
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Bedrosian Camille L Director · Common Stock · 2026-09-01 | Disposition | 5.92K | $504K | 2026-09-01 | 2026-09-01 |
Bedrosian Camille L Director · Common Stock · 2026-09-01 | Disposition | 16.3K | $1.4M | 2026-09-01 | 2026-09-01 |
Bedrosian Camille L Director · Stock Option (Right to Buy) · 2026-09-01 | Disposition | 25K | $1.7M | 2026-09-01 | 2026-09-01 |
Bedrosian Camille L Director · Stock Option (Right to Buy) · 2026-09-01 | Disposition | 17.5K | $1.1M | 2026-09-01 | 2026-09-01 |
Bedrosian Camille L Director · Stock Option (Right to Buy) · 2026-09-01 | Disposition | 17.5K | $1.2M | 2026-09-01 | 2026-09-01 |
Bedrosian Camille L Director · Stock Option (Right to Buy) · 2026-09-01 | Disposition | 17.5K | $1.1M | 2026-09-01 | 2026-09-01 |
Bedrosian Camille L Director · Stock Option (Right to Buy) · 2026-09-01 | Disposition | 12.5K | $504K | 2026-09-01 | 2026-09-01 |
Bedrosian Camille L Director · Stock Option (Right to Buy) · 2026-09-01 | Disposition | 10.35K | $545K | 2026-09-01 | 2026-09-01 |
Bedrosian Camille L Director · Stock Option (Right to Buy) · 2026-09-01 | Disposition | 9.73K | $478K | 2026-09-01 | 2026-09-01 |
Betz Stephen F. Chief Scientific Officer · Common Stock · 2026-09-01 | Disposition | 58.29K | $5.0M | 2026-09-01 | 2026-09-01 |
SEC filings
EDGAR filings in CRNX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.